NL-OMON45895尚未招募不适用
Single dose escalation study in a single center, randomized, single blind, placebo controlled, group comparison design to investigate pharmacokinetics, safety and tolerability of BAY 2253651 after intravenous administration in healthy male subjects. - Single dose escalation study.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- Bayer AG
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy white male volunteers
- •18 - 45 years of age
- •BMI 18.0 - 29.9 kilograms/meter2
- •non smokers
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior to the start of this study.
研究者
相似试验
已完成
不适用
Single dose escalation study in a single-center, randomized, single-blind, placebo-controlled, group-comparison design to investigate pharmacokinetics, safety and tolerability of BAY 2586116 after intravenous administration in healthy male participants.NL-OMON49427Bayer AG35
已完成
1 期
A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung canceron-small cell lung cancerJPRN-UMIN000007120Kanagawa Cancer Center18
进行中（未招募）
不适用
A single center, open-label, dose escalation study of the safety and pharmacokinetics of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-mannosidosis.Treatment of alpha-MannosidosisEUCTR2010-022084-36-DKZymenex A/S10
已完成
不适用
A single ascending dose escalation clinical trial to investigate safety and pharmacokinetics of VVZ-149 injection in healthy older male volunteersDiseases of the nervous systemKCT0001345Vivozon24
进行中（未招募）
1 期
An investigation to investigate whether a single dose of XEN-D0501 is tolerable by type 2 diabetic patients prior to multiple dose trials (to investigate if the compound can effectively regulate diabetes)Type 2 diabetesEUCTR2016-003843-12-DKPILA PHARMA26